/CLRB
CLRB Stock - Cellectar Biosciences, Inc.
Healthcare|BiotechnologyNASDAQ
$2.68-1.11%
$0.03 (-1.11%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+347.8%upside
Target: $12.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CLRB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.65 – $2.71
TARGET (TP)$12.00
STOP LOSS$2.47
RISK/REWARD1:44.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.47
52W High$20.70
52W Low$2.45
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-51,777,698 | $-38,960,643 | $-28,813,773 | $-24,131,280 | $-15,290,349 |
| Net Income | $-44,581,446 | $-42,770,610 | $-31,792,618 | $-24,122,362 | $-15,094,172 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-36.52 | $-104.99 | $-135.18 | $-130.35 | $-228.55 |
Company Overview
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$13
Average Target
↑ 385.1% Upside
Now
$13
Low
$13
Average
$13
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 5th 2024 | Ladenburg Thalmann | Resumed | Buy | $13 |
Earnings History & Surprises
CLRBBeat Rate
44%
Last 18 quarters
Avg Surprise
-8.6%
EPS vs Estimate
Beats / Misses
8/8
2 met exactly
Latest EPS
$-1.41
Q4 2025
EPS Surprise History
Q1 24
-11.9%
$-0.66vs$-0.59
Q2 24
+20.0%
$-0.40vs$-0.50
Q3 24
-217.4%
$-0.73vs$-0.23
Q4 24
-37.8%
$-0.51vs$-0.37
Q1 25
+97.4%
$-0.01vs$-0.38
Q2 25
+23.7%
$-3.90vs$-5.11
Q3 25
+5.8%
$-3.39vs$-3.60
Q4 25
+26.2%
$-1.41vs$-1.91
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 12, 2026 | $-1.20 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-1.91 | $-1.41 | +26.2% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-3.60 | $-3.39 | +5.8% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-5.11 | $-3.90 | +23.7% | ✓ BEAT |
Q1 2025 | Mar 13, 2025 | $-0.38 | $-0.01 | +97.4% | ✓ BEAT |
Q4 2024 | Oct 29, 2024 | $-0.37 | $-0.51 | -37.8% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-0.23 | $-0.73 | -217.4% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-0.50 | $-0.40 | +20.0% | ✓ BEAT |
Q1 2024 | Mar 27, 2024 | $-0.59 | $-0.66 | -11.9% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-0.44 | $-0.82 | -86.4% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-0.69 | $-0.73 | -5.8% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.75 | $-0.76 | -1.3% | ✗ MISS |
Q1 2023 | Mar 9, 2023 | $-0.83 | $-0.55 | +33.7% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-1.21 | $-1.28 | -5.8% | ✗ MISS |
Q3 2022 | Aug 5, 2022 | $-1.08 | $-1.22 | -13.0% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-1.10 | $-1.00 | +9.1% | ✓ BEAT |
Q1 2022 | Mar 21, 2022 | $-1.00 | $-1.00 | 0.0% | = MET |
Q4 2021 | Nov 8, 2021 | $-1.10 | $-1.00 | +9.1% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-1.10 | $-1.10 | 0.0% | = MET |
Latest News
Cellectar Biosciences Announces Multi-Year Supply Agreement With Ionetix For Actinium-225 And Astatine-211
📈 PositiveBenzinga•Dec 16, 2025, 01:08 PM•Also:
Cellectar Biosciences Q3 EPS $(1.41) Beats $(2.53) Estimate
📈 PositiveBenzinga•Nov 13, 2025, 12:03 PM
CLRB stock has given up its prior gain. Cellectar Biosciences shares were trading higher after the company received Rare Pediatric Disease designation from the FDA for Iopofosine I-131 in relapsed or refractory pediatric high-grade glioma.
➖ NeutralBenzinga•Oct 27, 2025, 01:27 PM
Cellectar Biosciences shares are trading higher after the company received Rare Pediatric Disease designation from the FDA for Iopofosine I-131 in relapsed or refractory pediatric high-grade glioma.
📈 PositiveBenzinga•Oct 27, 2025, 12:33 PM
Cellectar Biosciences Receives Rare Pediatric Disease Designation From FDA For Iopofosine I 131 In Relapsed or Refractory Pediatric High-Grade Glioma
📈 PositiveBenzinga•Oct 27, 2025, 12:32 PM
Cellectar Biosciences Presented Preclinical Data On CLR 121225, A Novel Actinium-Based Alpha-Emitter For Pancreatic Ductal Adenocarcinoma Which Has Completed IND-Enabling Studies And May Advance To A Phase 1 Trial
📈 PositiveBenzinga•Oct 14, 2025, 12:37 PM•Also:
Cellectar Biosciences enters into agreements to raise $5.8M
➖ NeutralSeeking Alpha•Oct 7, 2025, 12:42 PM
Cellectar Biosciences Secures $5.8M In Gross Proceeds Through Institutional Warrant Exercise
📈 PositiveBenzinga•Oct 7, 2025, 12:33 PM
Cellectar Eyes 2027 EU Launch As EMA Backs Conditional Approval Path For Its Blood Cancer Drug
📈 PositiveBenzinga•Oct 6, 2025, 11:08 AM
Cellectar Biosciences Highlights Presentations At American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer Sept. 25-28
📈 PositiveBenzinga•Sep 30, 2025, 12:38 PM
Evestia To Provide Cellectar With Full CRO Services For Upcoming Phase 1b Study Evaluating CLR 125 For Treatment Of Triple-Negative Breast Cancer
📈 PositiveBenzinga•Sep 24, 2025, 12:34 PM
Cellectar Biosciences To Present Preclinical Data On Novel Pancreatic Cancer Therapy At AACR Conference
📈 PositiveBenzinga•Sep 3, 2025, 12:08 PM
Cellectar To Present Interim Phase 1b Data On Iopofosine In Pediatric Brain Cancer At AACR Conference
📈 PositiveBenzinga•Aug 27, 2025, 12:09 PM
Cellectar Cuts Q2 Losses and Expenses
📈 PositiveThe Motley Fool•Aug 14, 2025, 11:48 AM
Frequently Asked Questions about CLRB
What is CLRB's current stock price?
Cellectar Biosciences, Inc. (CLRB) is currently trading at $2.68 per share. The stock has moved -1.11% today.
What is the analyst price target for CLRB?
The average analyst price target for CLRB is $12.00, based on 1 analyst.
What sector is Cellectar Biosciences, Inc. in?
Cellectar Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CLRB's market cap?
Cellectar Biosciences, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does CLRB pay dividends?
No, Cellectar Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAEON
AEON Biopharma, Inc.
$1.08
Mkt Cap: $0.0B
BOLT
Bolt Biotherapeutics, Inc.
$5.16
Mkt Cap: $0.0B
CING
Cingulate Inc.
$3.97
Mkt Cap: $0.0B
EVGN
Evogene Ltd.
$1.02
Mkt Cap: $0.0B
IMNN
Imunon, Inc.
$3.75
Mkt Cap: $0.0B
LYRA
Lyra Therapeutics, Inc.
$3.60
Mkt Cap: $0.0B
MBIO
Mustang Bio, Inc.
$1.09
Mkt Cap: $0.0B
MRKR
Marker Therapeutics, Inc.
$1.28
Mkt Cap: $0.0B
RNAZ
TransCode Therapeutics, Inc.
$7.92
Mkt Cap: $0.0B
SNSE
Sensei Biotherapeutics, Inc.
$8.86
Mkt Cap: $0.0B
Explore stocks similar to CLRB for comparison